“EFECTO DEL COMPUESTO HA2 EN EL TRATAMIENTO DE LEISHMANIASIS CUTÁNEA DISEMINADA EXPERIMENTAL”

Abstract

The Leishmaniasis is an endemic parasitosis that affects about one million people each year. It is a disabling disease and is identified as a chronic skin disease, caused by an intracellular protozoan parasite of the genus Leishmania. Travelers who have been infected in endemic areas, returning to their place of origin the disease is not detected early and treatment is inappropriate. Adding that drug therapies are toxic, the parasites are resistant to current treatments or naturally some patients do not respond to these drugs, the involvement of injury and general malaise turns into a crippling and debilitating disease. It is necessary to seek a new drug that eradicated the disease. We tested a new drug derived from the triaminoquinazolina with ferrocene (HA2) and already on the market: N-methyl glucantime and hydroxyurea in BALB/c mice, comparing the injury and its therapeutic effect. Noting that there is a remission of 90 to 100% in healing of skin lesions.